Clinical Trials Browser

Phase 2 × Recruiting × ADI PEG20 × Clear all

NCT06034977 2023-09-13

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular